V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008751 | 330010897 | 1.7 | 61.7 | Disease modification (D) | null | 2013-06-29 | CYTARABINE | null | null | 330021203 | CLADRIBINE |
| 330008752 | 330005545 | 0 | 77.4 | Palliative (P) | 2016-07-14 | 2016-07-14 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330021212 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 330008753 | 330005546 | 1.83 | 68.5 | Curative (C) | 2016-07-20 | 2016-07-20 | Carboplatin + Vinorelbine Oral | 02 | N | 330021212 | CAPECITABINE + CISPLATIN |
| 330008754 | 330012525 | 0 | 9.5 | Curative (C) | null | 2016-04-18 | ETOPOSIDE + IFOSFAMIDE + MTX | N | null | 330021215 | VIDE |
| 330008755 | 330005547 | 1.74 | 67.3 | null | 2015-05-05 | 2015-05-05 | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 01 | N | 330021236 | EP |
| 330008756 | 330005548 | 1.77 | 67.7 | Adjuvant (A) | 2014-04-01 | 2014-04-09 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | Y | N | 330021240 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330008757 | 330005549 | null | 45.8 | Neo-adjuvant (N) | 2016-06-14 | 2016-09-03 | Cetuximab + CISPLATIN + FLUOROURACIL | null | null | 330021284 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330008758 | 330009028 | 1.7 | 82 | Neo-adjuvant (N) | 2016-11-24 | 2016-11-28 | Pazopanib | 2 | N | 330021288 | DOXORUBICIN + IFOSFAMIDE |
| 330008759 | 330009029 | 1.66 | 53 | Palliative (P) | 2017-01-31 | 2017-02-03 | VIDE | N | N | 330021288 | DOXORUBICIN + GEMCITABINE |
| 330008760 | 330005553 | 1.67 | null | Palliative (P) | 2014-06-10 | 2014-07-12 | EP | 1 | N | 330021291 | EP/EMA |
| 330008761 | 330005554 | 1.58 | 119 | Curative (C) | 2015-01-07 | 2015-03-31 | Cyclophosphamide High Dose | N | N | 330021301 | FLUDARABINE + MELPHALAN |
| 330008762 | 330005555 | 1.76 | 62.5 | Curative (C) | 2016-05-22 | 2016-05-22 | Bevacizumab 7.5mg/kg | N | N | 330021301 | CVD |
| 330008763 | 330005555 | 1.71 | 93.7 | Palliative (P) | 2018-07-08 | 2018-07-08 | Cetuximab + CISPLATIN + FLUOROURACIL | 02 | N | 330021301 | BEP |
| 330008764 | 330005555 | 1.77 | null | Neo-adjuvant (N) | 2013-12-27 | 2013-12-27 | CISPLATIN + VINORELBINE | 2 | N | 330021301 | ETOPOSIDE + RITUXIMAB |
| 330008765 | 330005557 | 1.78 | 84.5 | Palliative (P) | 2017-01-08 | 2017-01-08 | CHLORAMBUCIL + RITUXIMAB | 02 | null | 330021309 | BORTEZOMIB + RITUXIMAB |
| 330008766 | 330005559 | null | null | Disease modification (D) | 2017-08-19 | 2017-08-22 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 2 | N | 330021317 | AML19 TRIAL |
| 330008767 | 330005561 | null | 71.2 | Palliative (P) | null | 2015-12-19 | ECX | y | N | 330021319 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008770 | 330005565 | 1.6 | 75.5 | Not known (9) | 2016-03-19 | 2016-03-23 | EMA/CO | N | N | 330021342 | CLADRIBINE |
| 330008771 | 330005567 | 1.8 | 73.9 | Palliative (P) | 2017-08-01 | 2017-08-02 | Vemurafenib | 2 | N | 330021349 | IRINOTECAN + MDG |
| 330008772 | 330010904 | 1.75 | 55.9 | Curative (C) | 2017-02-27 | 2017-03-10 | AML 19 TRIAL | N | N | 330021357 | FLUDARABINE |
| 330008773 | 330011933 | 1.59 | null | null | 2016-09-21 | 2016-10-01 | Cyclophosphamide High Dose | 02 | N | 330021361 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008774 | 330011933 | 1.67 | 78.9 | Neo-adjuvant (N) | 2015-05-06 | 2015-05-06 | VIDE | N | N | 330021361 | CYTARABINE |
| 330008775 | 330012867 | null | 74.6 | Adjuvant (A) | 2017-11-05 | 2017-11-05 | IPO | null | N | 330021363 | AML19 TRIAL |
| 330008776 | 330005569 | 1.76 | 21.4 | Palliative (P) | 2015-01-25 | 2015-01-25 | POMB/ACE | 02 | N | 330021366 | DOXORUBICIN + IFOSFAMIDE |
| 330008777 | 330005569 | 1.72 | 58 | Palliative (P) | 2017-12-06 | 2018-01-03 | DHAP | N | N | 330021366 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330008778 | 330005570 | 1.8 | 78.25 | Disease modification (D) | 2016-12-24 | 2016-12-24 | Clofarabine + Cytarabine | 2 | N | 330021390 | CLADRIBINE |
| 330008779 | 330005573 | null | 72.2 | Neo-adjuvant (N) | 2017-01-07 | 2017-01-12 | BEP 3 day | N | null | 330021390 | IBRUTINIB |
| 330008781 | 330005575 | null | 80 | Disease modification (D) | 2015-02-27 | 2015-02-28 | CVP R | N | null | 330021428 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330008782 | 330012528 | 1.61 | 77.1 | Curative (C) | 2015-11-15 | 2015-11-15 | Nilotinib | N | N | 330021432 | CETUXIMAB + CISPLATIN + FU |
| 330008786 | 330005581 | 1.73 | null | Disease modification (D) | 2016-08-09 | 2016-08-09 | BORTEZOMIB + THALIDOMIDE | 02 | N | 330021489 | CYCLOPHOSPHAMIDE |
| 330008787 | 330005583 | 1.85 | 120.1 | Curative (C) | null | 2016-07-16 | ETOPOSIDE + RITUXIMAB | N | N | 330021531 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330008788 | 330005583 | 1.6 | 57.9 | null | 2017-12-05 | 2017-12-05 | AML17 TRIAL | 02 | N | 330021531 | RUXOLITINIB |
| 330008790 | 330005585 | 1.69 | 49.7 | null | 2011-05-22 | 2014-08-13 | UKALL14- Ph 2 Induction | N | N | 330021553 | IPO |
| 330008791 | 330005585 | 0 | null | Palliative (P) | null | 2018-01-05 | BORTEZOMIB + RITUXIMAB | null | Y | 330021553 | VINCRISTINE |
| 330008792 | 330005585 | null | 67.4 | Neo-adjuvant (N) | null | 2017-07-23 | AML 18 TRIAL | null | N | 330021553 | IVADO |
| 330008793 | 330005585 | 1.85 | 73 | Neo-adjuvant (N) | null | 2016-03-31 | VINCRISTINE | null | null | 330021553 | INTERFERON |
| 330008794 | 330005585 | 1.67 | 101.2 | Curative (C) | 2014-07-11 | 2014-07-14 | Gemcitabine + Oxaliplatin | N | N | 330021553 | EDP |
| 330008795 | 330005586 | 1.69 | 47.8 | null | 2017-12-04 | 2017-12-11 | DACTINOMYCIN | N | N | 330021574 | MITOTANE |
| 330008796 | 330005587 | 1.69 | 119.5 | Palliative (P) | 2014-10-05 | 2014-10-19 | Capecitabine + Cisplatin | N | N | 330021579 | UKALL2014 |
| 330008797 | 330005587 | 1.69 | 59.4 | Adjuvant (A) | 2016-07-18 | 2016-07-21 | Mitotane 5.5 - 10g | 01 | null | 330021579 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008798 | 330005587 | 1.57 | 0 | Adjuvant (A) | 2017-02-23 | 2017-05-02 | PAC-E | N | N | 330021579 | FLUDARABINE + MELPHALAN |
| 330008799 | 330005588 | 1.69 | 67 | null | 2015-11-10 | 2015-11-10 | Carboplatin + Pemetrexed | N | N | 330021591 | CYCLOPHOSPHAMIDE |
| 330008800 | 330005589 | 1.57 | 71.6 | Palliative (P) | null | 2013-08-30 | Alemtuz+Fludara+Melphalan RIC MUD | null | N | 330021602 | PEMBROLIZUMAB |
| 330008801 | 330010914 | 0 | 90.85 | Curative (C) | 2018-09-07 | 2018-09-29 | Intensification 1 2 3(ALL) (Mtx) | 02 | N | 330021623 | HYDROXYCARBAMIDE |
| 330008802 | 330005595 | null | 72 | Disease modification (D) | 2017-11-28 | 2017-12-01 | Cyclophosphamide High Dose | null | null | 330021632 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330008803 | 330005595 | 1.64 | 78.9 | Disease modification (D) | 2017-09-30 | 2017-10-18 | CTD | N | N | 330021632 | TRIPLE INTRATHECAL |
| 330008804 | 330005597 | 1.74 | 79.05 | Curative (C) | 2015-02-21 | 2015-02-22 | FCarboSt | N | N | 330021653 | VIDE |
| 330008805 | 330005601 | 1.82 | 74 | Palliative (P) | null | 2017-08-13 | Vemurafenib | null | N | 330021660 | DOXORUBICIN + METHOTREXATE |
| 330008806 | 330005602 | null | 51.5 | Curative (C) | 2014-04-29 | 2014-05-17 | Bortezomib +/- Dexamethasone | N | null | 330021660 | AML16 TRIAL |
| 330008807 | 330005604 | 1.84 | null | Palliative (P) | 2013-04-26 | 2013-11-11 | BEP 5 Day | N | N | 330021673 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |